Mercaptopurine

Indication
Acute myeloid leukaemia with recurrent genetic abnormalities

INN
Mercaptopurine

Medicine type
Chemical agent

List type
Complementary (EML) (EMLc)

Formulations
Oral > Liquid: 20 mg per mL (EMLc)
Oral > Solid: 50 mg tablet

EML status history
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)

Sex
All

Age
Also recommended for children

Therapeutic alternatives
The recommendation is for this specific medicine

Patent information
Patents have expired in most jurisdictions
Read more about patents.

Tags
Cancer

Wikipedia
Mercaptopurine

DrugBank
Mercaptopurine

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of mercaptopurine (oral liquid 20 mg/mL) to the EMLc.